Matrilin-3
MATN3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | MATN3, DIPOA, EDM5, HOA, OADIP, OS2, matrilin 3, SEMDBCD | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 602109; MGI: 1328350; HomoloGene: 1785; GeneCards: MATN3; OMA:MATN3 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Matrilin-3 is a protein that in humans is encoded by the MATN3 gene.[5][6][7] It is linked to the development of many types of cartilage,[8] and part of the Matrilin family, which includes Matrilin-1, Matrilin-2, Matrilin-3, and Matrilin-4, a family of filamentous-forming adapter oligomeric extracellular proteins that are linked to the formation of cartilage and bone, as well as maintaining homeostasis after development.[8] It is considered an extracellular matrix protein that functions as an adapter protein[9] where the Matrilin-3 subunit can form both homo-tetramers and hetero-oligomers with subunits from Matrilin-1 which is the cartilage matrix protein. This restricted tissue has been strongly expressed in growing skeletal tissue as well as cartilage and bone.[8][10]
Each member of the Matrilin family consist of one or two Von Willebrand Factor A (vWFA) domains, several epidermal growth factor (EGF)- like domains, and an alpha-helical coiled-coil domain.[9] Matrilin-3 does not contain the second vWFA -like domain that is present in the rest of the members of the Matrilin family.[11] It is considered the shortest and least complex member of the family, consisting of only one Von Willebrand Factor A domain, four epidermal growth factor domains, and a C-terminal coiled-coil domain.[8][9] The Matrilin-3 protein is considered a multimeric protein that can form bonds to triple helix collagens, decorin and biglycan, as it plays an important role as a linker molecule in the formation of the articular cartilage network.[12]
Function of Matrilin-3
[edit]The main function of Matrilin-3 is to enhance Collagen II and aggrecan expression which is essential in maintaining the elasticity and strength of cartilage. Not only does it maintain cartilage structure but also its function and disease development.[9] Matrilin-3 is mainly expressed in cartilage before birth, unless linked to disease development during adulthood.
Structure
[edit]The matrilin-3 protein was assigned to chromosome region 2 (2p24 - p23) with the corresponding mRNA of 2.8kb which has been found expressed in every type of cartilage investigated.[13][8] Matrilin-3 is arranged in 7 domains and is composed of 486 amino acid residues. The nucleotide sequence for Matrilin-3 in humans is 83% similar to the Matrilin-3 in mice, and 61% similar to that of chicken.[8] The main differences between the different species differ mainly in the positively charged N-terminal domain, which is shorter in chicken compared to the Human Matrilin-3. The chicken Matrilin-3 also differs as it does not contain an insertion of a single aspartic acid residue in their four EGF -like domains, like in the human and mouse Matrilin-3 sequences.[11]
In mice, Matrilin-3 is only expressed in the development of cartilage of the skeletal system. However, although Matrilin-1 continues to be expressed in tissues that remain cartilaginous throughout its life, Matrilin-3 is not presently expressed in these tissues after birth.[8] Preliminary Immunoblot test result in the expression of Matrilin-3 being much higher in the fetal tissues than in adult.[11] However, this does not mean that Matrilin-3 can not be expressed in mature cartilage. There is a strong correlation between strong Matrilin-3 gene expression and tissue damage.[10] Strong Matrilin-3 gene expression has been consistently linked to development of osteoarthritis, which can develop from high levels of Matrilin-3 which tears down articular cartilage, resulting loss in not only the surface are but proliferating and hypertrophic areas.[8]
Matrilin-3 plays a crucial role in keeping structural integrity of cartilage an extracellular matrix, and has been shown to have increased levels in osteoarthritis, and is also expressed in bone under normal conditions. It is also regulates extracellular matrix components of bone.[9] Matrilin-3 interacts with TGF-β and BMP-2 to maintain homeostasis for the extracellular matrix of cartilage, as well as maintain chondrocytes during development.[9] The types of cartilage that Matrilin-3 has been observed in are cartilaginous tissue, which includes articular and epiphyseal cartilage, as well as in cartilaginous anlage of developing bones.[9] Matrilin-3 is essential in the formation of collagen-dependent networks as it connects the collagen independent pericellular network and cells, forming the filamentous connections.[9] In skeletal development, Matrilin-3 is involved in mesenchymal differentiation, de-differentiation, chondrocyte terminal differentiation, and bone mineral density maintenance.[9]
Correlation to disease
[edit]Osteoarthritis is caused by polymorphisms and mutations in several genes, especially Matrilin-3.[9] Matrilin-3 mutations are linked to skeletal diseases like osteoarthritis, and chondrodysplasias like multiple epiphyseal dysplasia (MED) and spondyloepimetaphyseal dysplasia.[8] A correlation between people with multiple epiphyseal dysplasia, or MED, has been linked to mutations in the vWFA domain of the Matrilin-3 protein.(ncbi) Point mutations in Matrilin-3 can affect protein folding and trafficking, as Matrilin-3 is retained and accumulated in the endoplasmic reticulum, leading to a reduced formation of filamentous networks around the cells.[9] Matrilin-3 has also been shown to increase collagen II and aggrecan, while reducing ADAMTS5 and MMP-13 in chondrocytes, which suggest that there is a reduction of hypertrophy caused by inflammation.[9]
It was also shown that when Matrilin-3 is bound to BMP2,the BMP receptor-mediated Smad1 phosphorylation and collagen X expression are prevented in chondrocytes, which designates that Matrilin-3 can act as an antagonist to prevent hypertrophic terminal differentiation of chondrocytes.[9] The binding of Matrilin-3 altogether, increases AKT phosphorylation, increasing chondrocyte survival and ECM synthesis.[9] The folding of the protein structure caused by MED-causing mutations, are most noticeably found in the B strands of the center of the vWFA domain.[8] As Matrilin-3 is associated with skeletal diseases like Osteoarthritis, levels are shown to be increased and present in middle and deep cartilage zone, and possibly the subchondral bone as well. In bone, Matrilin-3 is not only found in not yet resorbed calcified cartilage but it is also actively synthesized by osteoblast and osteocytes.[11]
Conclusion
[edit]The Matrilin-3 protein is protein linked to the development of cartilage and bone, and consists of one Von Willebrand Factor A domain, four epidermal growth factor domains, and a C-terminal coiled-coil domain.[8][9] Matrilin-3 expression is mostly present in the development of cartilage prior to birth, and ceases to exist in adulthood unless linked with skeletal diseases like osteoarthritis, and chondrodysplasias like multiple epiphyseal dysplasia (MED) and spondyloepimetaphyseal dysplasia.[8] The main function of Matrilin-3 is to enhance Collagen II and aggrecan expression which is essential in maintaining the elasticity and strength of cartilage.[9]
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000132031 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000020583 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Wagener R, Kobbe B, Paulsson M (Oct 1997). "Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor". FEBS Lett. 413 (1): 129–34. doi:10.1016/S0014-5793(97)00895-8. PMID 9287130. S2CID 44885277.
- ^ Belluoccio D, Trueb B (Nov 1997). "Matrilin-3 from chicken cartilage". FEBS Lett. 415 (2): 212–6. doi:10.1016/S0014-5793(97)01126-5. PMID 9350998. S2CID 10734417.
- ^ "Entrez Gene: MATN3 matrilin 3".
- ^ a b c d e f g h i j k l Wang YC, Liu JS, Chen JY, Wu SQ, Wang GR, Nie J, Zhang SK, Guo QL, Luo JM (2015-12-01). "Multiple functions of the first EGF domain in matrilin-3: Secretion and endoplasmic reticulum stress". International Journal of Molecular Medicine. 36 (6): 1648–1656. doi:10.3892/ijmm.2015.2377. ISSN 1107-3756. PMID 26499313.
- ^ a b c d e f g h i j k l m n o p Muttigi M, Han I, Park HK, Park H, Lee SH (2016-04-20). "Matrilin-3 Role in Cartilage Development and Osteoarthritis". International Journal of Molecular Sciences. 17 (4): 590. doi:10.3390/ijms17040590. ISSN 1422-0067. PMC 4849044. PMID 27104523.
- ^ a b Pullig O, Weseloh G, Klatt AR, Wagener R, Swoboda B (2002-04-01). "Matrilin-3 in human articular cartilage: increased expression in osteoarthritis". Osteoarthritis and Cartilage. 10 (4): 253–263. doi:10.1053/joca.2001.0508. ISSN 1063-4584. PMID 11950247.
- ^ a b c d Klatt AR, Nitsche DP, Kobbe B, Mörgelin M, Paulsson M, Wagener R (2000-02-11). "Molecular Structure and Tissue Distribution of Matrilin-3, a Filament-forming Extracellular Matrix Protein Expressed during Skeletal Development*". Journal of Biological Chemistry. 275 (6): 3999–4006. doi:10.1074/jbc.275.6.3999. ISSN 0021-9258. PMID 10660556.
- ^ Lories RJ, Luyten FP (2018-01-01), Thakker RV, Whyte MP, Eisman JA, Igarashi T (eds.), "Chapter 13 - Overview of Joint and Cartilage Biology", Genetics of Bone Biology and Skeletal Disease (Second Edition), Academic Press, pp. 209–225, ISBN 978-0-12-804182-6, retrieved 2023-04-27
- ^ Belluoccio D, Schenker T, Baici A, Trueb B (1998-11-01). "Characterization of Human Matrilin-3 (MATN3)". Genomics. 53 (3): 391–394. doi:10.1006/geno.1998.5519. ISSN 0888-7543. PMID 9799608.
External links
[edit]Further reading
[edit]- Belluoccio D, Schenker T, Baici A, Trueb B (1998). "Characterization of human matrilin-3 (MATN3)". Genomics. 53 (3): 391–4. doi:10.1006/geno.1998.5519. PMID 9799608.
- Sanger Centre T, Washington University Genome Sequencing Cente T (1999). "Toward a complete human genome sequence". Genome Res. 8 (11): 1097–108. doi:10.1101/gr.8.11.1097. PMID 9847074.
- Chapman KL, Mortier GR, Chapman K, et al. (2001). "Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia". Nat. Genet. 28 (4): 393–6. doi:10.1038/ng573. PMID 11479597. S2CID 8316621.
- Frank S, Schulthess T, Landwehr R, et al. (2002). "Characterization of the matrilin coiled-coil domains reveals seven novel isoforms". J. Biol. Chem. 277 (21): 19071–9. doi:10.1074/jbc.M202146200. PMID 11896063.
- Stefánsson SE, Jónsson H, Ingvarsson T, et al. (2003). "Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3". Am. J. Hum. Genet. 72 (6): 1448–59. doi:10.1086/375556. PMC 1180305. PMID 12736871.
- Jackson GC, Barker FS, Jakkula E, et al. (2004). "Missense mutations in the beta strands of the single A-domain of matrilin-3 result in multiple epiphyseal dysplasia". J. Med. Genet. 41 (1): 52–9. doi:10.1136/jmg.2003.011429. PMC 1757268. PMID 14729835.
- Mäkitie O, Mortier GR, Czarny-Ratajczak M, et al. (2004). "Clinical and radiographic findings in multiple epiphyseal dysplasia caused by MATN3 mutations: description of 12 patients". Am. J. Med. Genet. A. 125 (3): 278–84. doi:10.1002/ajmg.a.20486. PMID 14994237. S2CID 22407745.
- Borochowitz ZU, Scheffer D, Adir V, et al. (2004). "Spondylo-epi-metaphyseal dysplasia (SEMD) matrilin 3 type: homozygote matrilin 3 mutation in a novel form of SEMD". J. Med. Genet. 41 (5): 366–72. doi:10.1136/jmg.2003.013342. PMC 1735768. PMID 15121775.
- Mabuchi A, Haga N, Maeda K, et al. (2005). "Novel and recurrent mutations clustered in the von Willebrand factor A domain of MATN3 in multiple epiphyseal dysplasia". Hum. Mutat. 24 (5): 439–40. doi:10.1002/humu.9286. PMID 15459972. S2CID 29416307.
- Hecht JT, Hayes E, Haynes R, Cole WG (2005). "COMP mutations, chondrocyte function and cartilage matrix". Matrix Biol. 23 (8): 525–33. doi:10.1016/j.matbio.2004.09.006. PMID 15694129.
- Otten C, Wagener R, Paulsson M, Zaucke F (2006). "Matrilin-3 mutations that cause chondrodysplasias interfere with protein trafficking while a mutation associated with hand osteoarthritis does not". J. Med. Genet. 42 (10): 774–9. doi:10.1136/jmg.2004.029462. PMC 1735938. PMID 16199550.
- Cotterill SL, Jackson GC, Leighton MP, et al. (2006). "Multiple epiphyseal dysplasia mutations in MATN3 cause misfolding of the A-domain and prevent secretion of mutant matrilin-3". Hum. Mutat. 26 (6): 557–65. doi:10.1002/humu.20263. PMC 2726956. PMID 16287128.
- Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
- Eliasson GJ, Verbruggen G, Stefansson SE, et al. (2006). "Hand radiology characteristics of patients carrying the T(303)M mutation in the gene for matrilin-3". Scand. J. Rheumatol. 35 (2): 138–42. doi:10.1080/03009740500303215. PMID 16641049. S2CID 19719710.
- Maeda K, Horikoshi T, Nakashima E, et al. (2007). "MATN and LAPTM are parts of larger transcription units produced by intergenic splicing: intergenic splicing may be a common phenomenon". DNA Res. 12 (5): 365–72. doi:10.1093/dnares/dsi017. PMID 16769693.
- Hills R, Mazzarella R, Fok K, et al. (2007). "Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate". J. Biol. Chem. 282 (15): 11101–9. doi:10.1074/jbc.M611588200. PMID 17311924.
- Leighton MP, Nundlall S, Starborg T, et al. (2007). "Decreased chondrocyte proliferation and dysregulated apoptosis in the cartilage growth plate are key features of a murine model of epiphyseal dysplasia caused by a matn3 mutation". Hum. Mol. Genet. 16 (14): 1728–41. doi:10.1093/hmg/ddm121. PMC 2674230. PMID 17517694.